The CARES Approach: Improving Glycemic, Cardiovascular and Renal Outcomes
Questions marked with a
Meta-analyses for the SGLT2 inhibitor trials EMPA-REG, CANVAS, and DECLARE-TIMI demonstrated which of the following?
Reduced hazard ratios for the progression of chronic kidney disease with SGLT2 inhibitors vs placebo
Reduced hazard ratios for the development of bone fractures with SGLT2 inhibitors vs placebo
Increased hazard ratios for MACE with SGLT2 inhibitors vs placebo
Increased hazard ratios for heart failure hospitalizations with SGLT2 inhibitors vs placebo
Continue Without Answering